GO:0002003 angiotensin maturation: Peptide Activation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002003 angiotensin maturation is the biological process that converts angiotensinogen into mature angiotensin peptides in the blood.
• The process is initiated by renin, which cleaves angiotensinogen to angiotensin I, and completed by angiotensin-converting enzyme (ACE), which generates angiotensin II.
• Mature angiotensin II acts on AT1 and AT2 receptors to regulate blood pressure, fluid balance, and cardiovascular remodeling.
• Alternative maturation routes involving ACE2, angiotensin-(1-7), and the Mas receptor produce vasodilatory and antifibrotic effects.
• Angiotensin peptides are measurable in low-volume samples, enabling pediatric and clinical studies of the renin-angiotensin-aldosterone system.
• Dysregulated angiotensin maturation contributes to hypertension, heart failure, renal disease, and reproductive disorders.
Description
Angiotensin maturation (GO:0002003) is the biological process that generates the full functional capacity of angiotensin by converting angiotensinogen into mature angiotensin in the blood. This process is central to the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that controls blood pressure, electrolyte balance, and cardiovascular homeostasis. The maturation cascade begins when renin, released by the kidneys, cleaves angiotensinogen to produce angiotensin I, which is then processed by angiotensin-converting enzyme (ACE) to yield the octapeptide angiotensin II. Angiotensin II is the principal effector peptide, acting through AT1 and AT2 receptors to modulate vasoconstriction, aldosterone secretion, and sodium retention. Beyond the classical renin-ACE axis, alternative maturation pathways involving ACE2, angiotensin-(1-7), and the Mas receptor generate peptides with opposing, vasodilatory, and antifibrotic properties. These pathways are increasingly recognized in reproductive biology, where angiotensin-(1-7) in follicular fluid correlates with oocyte maturation, and in gonadal function through ACE2 and Mas receptor signaling. The maturation process is also developmentally regulated, with distinct angiotensin peptide profiles in healthy children compared to those with cardiovascular or renal disease. For researchers, angiotensin maturation represents a tractable biological process for studying proteolytic cascades, receptor pharmacology, and disease mechanisms. The availability of low-volume LC-MS assays for aldosterone and its precursors has enabled precise quantification of RAAS maturation intermediates in pediatric populations. Synthetic nanobodies that block angiotensin receptors provide novel tools for dissecting receptor-specific functions. Understanding the molecular steps and regulatory nodes of angiotensin maturation is therefore essential for developing targeted therapies in cardiovascular, renal, and reproductive medicine.
angiotensin maturation At A Glance
| GO ID | GO:0002003 |
|---|---|
| GO term | angiotensin maturation |
| Ontology | biological_process |
| Synonym | angiotensin catabolic process in blood |
| Major function | Conversion of angiotensinogen into mature angiotensin peptides in the blood |
| Key enzymes | Renin, angiotensin-converting enzyme (ACE), ACE2 |
| Key peptides | Angiotensin I, angiotensin II, angiotensin-(1-7) |
| Key receptors | AT1 receptor, AT2 receptor, Mas receptor |
| Physiological role | Regulation of blood pressure, fluid balance, and cardiovascular homeostasis |
What Is GO:0002003?
Angiotensin maturation is the process leading to the attainment of the full functional capacity of angiotensin by conversion of angiotensinogen into mature angiotensin in the blood. In other words, it encompasses the proteolytic cleavage events that transform the inactive precursor angiotensinogen into bioactive angiotensin peptides, primarily angiotensin II, which can then bind and activate angiotensin receptors. This process is synonymous with angiotensin catabolic process in blood, reflecting the sequential enzymatic processing of the angiotensinogen precursor.
Why Is angiotensin maturation Important in Cell Biology?
Angiotensin maturation is critically important because it governs the production of the principal vasoactive peptides that control blood pressure and cardiovascular function. Dysregulation of this process is directly implicated in hypertension, heart failure, and renal disease, making it a major therapeutic target. The maturation cascade also influences reproductive biology, as angiotensin-(1-7) levels in follicular fluid correlate with oocyte maturation, and ACE2/Mas receptor signaling modulates gonadal function. Furthermore, the developmental maturation of the RAAS in children differs from adults, with implications for pediatric cardiovascular and renal disease. Understanding angiotensin maturation at the molecular level enables the design of receptor blockers, enzyme inhibitors, and nanobody-based therapeutics.
• Controls blood pressure through angiotensin II-mediated vasoconstriction and aldosterone secretion.
• Regulates fluid and electrolyte balance via AT1 receptor signaling in the kidney.
• Influences cardiovascular remodeling and pathogenesis of heart failure.
• Modulates reproductive processes including oocyte maturation and gonadal function.
• Provides biomarkers for pediatric cardiovascular and renal disease through peptide profiling.
• Enables pharmacological intervention with ACE inhibitors and angiotensin receptor blockers.
• Involves alternative ACE2/angiotensin-(1-7)/Mas axis with protective, antifibrotic effects.
• Requires precise analytical methods for quantifying maturation intermediates in low-volume samples.
• Serves as a model for studying proteolytic cascades and peptide hormone maturation.
• Has implications for understanding developmental changes in RAAS activity from childhood to adulthood.
What Happens During angiotensin maturation?
Initiation by renin cleavage of angiotensinogen
In simple terms: Renin cuts a large precursor protein to start the maturation process.
The first step in angiotensin maturation is the cleavage of angiotensinogen by the enzyme renin, which is released from the juxtaglomerular cells of the kidney. Renin binds to and cleaves the N-terminal segment of angiotensinogen to release the decapeptide angiotensin I. This step is rate-limiting for the entire cascade and is tightly regulated by renal perfusion pressure, sodium balance, and sympathetic tone. The renin/prorenin receptor can also modulate this process by enhancing renin activity on the cell surface.
Conversion of angiotensin I to angiotensin II by ACE
In simple terms: A second enzyme trims angiotensin I to make the active hormone angiotensin II.
Angiotensin I is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE), a zinc-dependent dipeptidyl carboxypeptidase primarily expressed on the surface of endothelial cells in the lungs and kidneys. ACE removes two C-terminal amino acids from angiotensin I to generate the octapeptide angiotensin II. Angiotensin II is the principal bioactive peptide of the RAAS, exerting its effects through binding to AT1 and AT2 receptors. This conversion step is the target of ACE inhibitor drugs widely used to treat hypertension and heart failure.
Alternative maturation via ACE2 and angiotensin-(1-7)
In simple terms: A different enzyme can process angiotensin II into a protective peptide.
Angiotensin II can be further processed by angiotensin-converting enzyme 2 (ACE2), which removes a single amino acid to produce angiotensin-(1-7). Angiotensin-(1-7) binds to the Mas receptor and exerts vasodilatory, antifibrotic, and antiproliferative effects that oppose those of angiotensin II. This alternative maturation pathway is important in gonadal and reproductive functions, where ACE2 and Mas receptor signaling modulate follicular development and oocyte maturation. The balance between ACE/angiotensin II and ACE2/angiotensin-(1-7) axes determines the net biological outcome of angiotensin maturation.
Receptor-mediated signaling of mature angiotensin peptides
In simple terms: The mature peptides bind to receptors on cells to trigger physiological responses.
Mature angiotensin II binds primarily to AT1 receptors, which are G protein-coupled receptors that activate phospholipase C, increase intracellular calcium, and promote vasoconstriction, aldosterone release, and sodium retention. AT2 receptors generally mediate opposing effects, including vasodilation and antiproliferation. The expression of angiotensin receptors is developmentally regulated and can change in disease states, contributing to pathogenesis. Synthetic nanobodies that block angiotensin receptors have been developed as research tools to dissect receptor-specific signaling.
Developmental and clinical measurement of angiotensin maturation
In simple terms: The maturation process changes with age and can be measured in blood samples.
The maturation of the RAAS is developmentally regulated, with distinct angiotensin peptide profiles in neonates, children, and adults. A low-volume LC-MS assay has been developed for simultaneous determination of aldosterone, its precursor, and main metabolite, enabling studies in pediatric populations. Levels of angiotensin peptides in healthy children differ from those with cardiovascular or renal disease, suggesting that maturation intermediates can serve as biomarkers. These analytical advances support clinical research into RAAS maturation and its role in disease.
Key Genes Involved in GO:0002003 angiotensin maturation
The following genes and proteins are central to angiotensin maturation, encompassing the precursor, enzymes, peptides, and receptors that mediate the process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGT | Angiotensinogen precursor; substrate for renin | Source of all angiotensin peptides; polymorphisms linked to hypertension |
| REN | Renin; cleaves angiotensinogen to angiotensin I | Rate-limiting enzyme; target for renin inhibitors |
| ACE | Angiotensin-converting enzyme; converts angiotensin I to angiotensin II | Target of ACE inhibitors; key regulator of blood pressure |
| ACE2 | Converts angiotensin II to angiotensin-(1-7) | Protective axis; receptor for SARS-CoV-2; reproductive functions |
| AGTR1 | AT1 receptor; mediates angiotensin II effects | Target of angiotensin receptor blockers (ARBs) |
| AGTR2 | AT2 receptor; opposes AT1 effects | Mediates vasodilation and antiproliferation |
| MAS1 | Mas receptor; binds angiotensin-(1-7) | Mediates vasodilatory and antifibrotic effects |
| ATP6AP2 | Renin/prorenin receptor; enhances renin activity | Modulates local RAAS activation |
| CMA1 | Chymase; alternative angiotensin II-generating enzyme | Contributes to angiotensin II formation in tissues |
| ANPEP | Aminopeptidase N; degrades angiotensin peptides | Regulates peptide half-life |
| ENPEP | Aminopeptidase A; converts angiotensin II to angiotensin III | Generates alternative active peptides |
| LNPEP | Leucyl/cystinyl aminopeptidase; produces angiotensin IV | Generates angiotensin IV with distinct functions |
| NR3C2 | Mineralocorticoid receptor; mediates aldosterone effects | Downstream effector of angiotensin II-aldosterone axis |
| CYP11B2 | Aldosterone synthase; produces aldosterone | Regulated by angiotensin II; key in RAAS |
| AGTRAP | AT1 receptor-associated protein; modulates receptor trafficking | Regulates angiotensin II signaling |
| PRCP | Prolylcarboxypeptidase; generates angiotensin-(1-7) | Alternative pathway for angiotensin-(1-7) production |
| THOP1 | Thimet oligopeptidase; degrades angiotensin peptides | Regulates peptide turnover |
How Is angiotensin maturation Regulated?
Angiotensin maturation is regulated at multiple levels. Renin release is controlled by renal baroreceptors, macula densa sodium sensing, and sympathetic beta-1 adrenergic signaling. ACE activity is influenced by ACE inhibitors and by genetic polymorphisms. The ACE2/angiotensin-(1-7)/Mas axis is regulated by hormonal and developmental factors, with evidence for modulation during oocyte maturation and gonadal function. In children, the RAAS maturation profile changes with age, reflecting developmental regulation of enzyme and receptor expression. Synthetic nanobodies can block angiotensin receptors, providing tools to study receptor-specific regulation.
angiotensin maturation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACE | Hypertension, heart failure | ACE knockout or point-mutation cell models; ACE inhibitor studies |
| AGTR1 | Hypertension, cardiac hypertrophy | AT1 receptor knockout or overexpression models |
| ACE2 | Cardiovascular protection, COVID-19 susceptibility | ACE2 knockout or knock-in models; viral entry studies |
| AGT | Hypertension, preeclampsia | Angiotensinogen knockout or point-mutation models |
| REN | Renal disease, hypertension | Renin knockout or overexpression models |
Cardiovascular and renal disease
Dysregulated angiotensin maturation is a hallmark of hypertension, heart failure, and chronic kidney disease. Excessive angiotensin II production via ACE leads to vasoconstriction, sodium retention, and cardiac remodeling, which are mitigated by ACE inhibitors and angiotensin receptor blockers. In pediatric populations, altered angiotensin peptide levels are associated with cardiovascular and renal disease, and low-volume LC-MS assays can quantify these intermediates for diagnostic and prognostic purposes. The renin/prorenin receptor also contributes to tissue RAAS activation in renal disease.
Reproductive disorders
Angiotensin maturation components are expressed in reproductive tissues, where they influence follicular development and oocyte maturation. Angiotensin-(1-7) levels in human follicular fluid correlate with oocyte maturation, suggesting a role in fertility. ACE2, angiotensin-(1-7), and Mas receptor signaling modulate gonadal and reproductive functions, with potential implications for polycystic ovary syndrome and other fertility disorders. Intragonadal regulation of follicular maturation involves complex interactions with the RAAS.
Therapeutic targeting of angiotensin maturation
The angiotensin maturation cascade is a validated drug target. ACE inhibitors and angiotensin receptor blockers are mainstays of cardiovascular therapy. Synthetic nanobodies that block angiotensin receptors offer novel therapeutic modalities with potential for greater specificity. Modulating the ACE2/angiotensin-(1-7)/Mas axis may provide protective effects in cardiovascular and renal disease. Understanding the developmental maturation of the RAAS is essential for safe and effective pediatric therapeutics.
From angiotensin maturation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ACE reduce angiotensin II production? | ACE knockout cell line (e.g., HUVEC or HEK293) |
| Does a point mutation in AGT affect renin cleavage? | AGT point-mutation knock-in cell model |
| Can ACE2 overexpression increase angiotensin-(1-7)? | ACE2 overexpression cell line |
| How does AT1 receptor tagging affect signaling? | Tagged AT1 receptor knock-in cell line |
| Does Mas receptor knockout alter angiotensin-(1-7) effects? | MAS1 knockout cell model |
| Can CRISPR library screening identify regulators of angiotensin maturation? | Genome-wide CRISPR knockout library in RAAS-competent cells |
How to Study the angiotensin maturation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS | Angiotensin peptides and aldosterone precursors | Clinical pediatric RAAS profiling |
| CRISPR knockout screening | Genes regulating angiotensin maturation | Discovery of novel RAAS modulators |
| Calcium flux assay | AT1 receptor activation by angiotensin II | Receptor pharmacology |
| ELISA | Angiotensin II or angiotensin-(1-7) levels | Large cohort biomarker studies |
| Western blot | Protein expression of RAAS enzymes | Validation of knockout or overexpression |
| qRT-PCR | mRNA levels of AGT, REN, ACE, ACE2 | Transcriptional regulation studies |
| Nanobody-based blocking assay | Receptor-specific angiotensin effects | Therapeutic development |
LC-MS for angiotensin peptide quantification
Liquid chromatography-mass spectrometry (LC-MS) enables simultaneous quantification of angiotensin peptides and aldosterone precursors in low-volume blood samples. This method has been validated for pediatric studies, allowing precise measurement of angiotensin maturation intermediates. LC-MS provides high sensitivity and specificity compared to immunoassays, making it ideal for clinical research.
CRISPR screening for regulators of angiotensin maturation
Genome-wide CRISPR knockout or activation screens can identify genes that regulate angiotensin maturation. Using RAAS-competent cell lines and reporters for angiotensin II or angiotensin-(1-7), researchers can uncover novel enzymes, transporters, or signaling components. This approach is powerful for discovering unappreciated modulators of the cascade.
Reporter assays and receptor signaling
Luciferase or fluorescent reporters driven by angiotensin receptor activation can measure maturation efficiency. AT1 receptor-mediated calcium flux or beta-arrestin recruitment assays are commonly used to assess angiotensin II activity. Nanobody-based blockers can validate receptor specificity.
Immunoassays and ELISA for angiotensin peptides
Enzyme-linked immunosorbent assays (ELISAs) are widely used to measure angiotensin II and angiotensin-(1-7) in plasma and tissue samples. While less precise than LC-MS, they are suitable for high-throughput screening and large cohort studies. Cross-reactivity with related peptides must be validated.
How CRISPR Can Be Used to Study GO:0002003 angiotensin maturation
Knockout
CRISPR knockout of ACE, AGTR1, or MAS1 in cell models can abolish specific arms of angiotensin maturation, allowing researchers to dissect their contributions to downstream signaling. For example, ACE knockout prevents angiotensin II generation, while MAS1 knockout eliminates angiotensin-(1-7) effects. These models are essential for validating drug targets and understanding compensatory pathways.
Point Mutation
Point mutations in AGT or REN can mimic naturally occurring variants that alter cleavage efficiency or substrate affinity. CRISPR-mediated knock-in of such mutations enables study of their impact on angiotensin maturation and disease susceptibility. For instance, mutations affecting the renin cleavage site can be modeled to assess hypertensive risk.
Knock-in
Knock-in of tagged versions of AT1 receptor or ACE2 allows real-time tracking of receptor trafficking and localization. Tagged knock-in models are valuable for imaging studies and for isolating receptor complexes. This approach can reveal how maturation peptides interact with their receptors in live cells.
Overexpression
CRISPR activation or cDNA overexpression of ACE2 or angiotensin-(1-7) can enhance the protective arm of the RAAS. Overexpression models are used to test whether increasing angiotensin-(1-7) production ameliorates cardiovascular or renal injury. These models also help identify rate-limiting steps in angiotensin maturation.
How EDITGENE Supports angiotensin maturation Research
Researchers studying angiotensin maturation-related genes often need to determine whether a candidate gene is causally involved in peptide processing, receptor signaling, or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes in the angiotensin maturation pathway.
Contact EDITGENE today to design your custom CRISPR model for angiotensin maturation research.
Frequently Asked Questions About angiotensin maturation
What is angiotensin maturation?
Angiotensin maturation is the biological process that converts angiotensinogen into mature angiotensin peptides, primarily angiotensin II, in the blood.
What genes are involved in angiotensin maturation?
Key genes include AGT, REN, ACE, ACE2, AGTR1, AGTR2, and MAS1, which encode the precursor, enzymes, and receptors of the cascade.
What is the GO ID for angiotensin maturation?
The Gene Ontology ID for angiotensin maturation is GO:0002003.
How is angiotensin II produced?
Angiotensin II is produced by sequential cleavage of angiotensinogen by renin to angiotensin I, followed by ACE-mediated conversion to angiotensin II.
What is the role of ACE2 in angiotensin maturation?
ACE2 converts angiotensin II to angiotensin-(1-7), which binds the Mas receptor and exerts vasodilatory and antifibrotic effects.
How can I study angiotensin maturation in the lab?
Common methods include LC-MS for peptide quantification, CRISPR knockout of RAAS genes, and receptor signaling assays.
What diseases are linked to angiotensin maturation?
Dysregulated angiotensin maturation is linked to hypertension, heart failure, renal disease, and reproductive disorders.
Can CRISPR be used to model angiotensin maturation defects?
Yes, CRISPR knockout, point mutation, and knock-in models can recapitulate genetic defects in RAAS genes.
What is the difference between angiotensin I and angiotensin II?
Angiotensin I is an inactive decapeptide, while angiotensin II is the active octapeptide produced by ACE-mediated cleavage.
How is angiotensin maturation measured in children?
Low-volume LC-MS assays can simultaneously measure aldosterone, its precursor, and main metabolite in pediatric samples.
Conclusion
Angiotensin maturation (GO:0002003) is a fundamental biological process that generates the active peptides controlling blood pressure, fluid balance, and cardiovascular health. The cascade involves renin, ACE, ACE2, and multiple receptors, with alternative pathways producing protective peptides such as angiotensin-(1-7). Dysregulation of this process underlies major diseases including hypertension, heart failure, and reproductive disorders. Advances in LC-MS and CRISPR technologies are enabling precise interrogation of angiotensin maturation in health and disease. Targeting this pathway remains a cornerstone of cardiovascular therapeutics, and ongoing research continues to uncover new regulatory mechanisms and therapeutic opportunities.
References
- 1. Kintscher U et al.. 2003. Angiotensin II receptor expression: from maturation to pathogenesis.. Am J Physiol Regul Integr Comp Physiol 285(1):R26-7 PMID: 12793989
- 2. Cavallo IK et al.. 2017. Angiotensin-(1-7) in human follicular fluid correlates with oocyte maturation.. Hum Reprod 32(6):1318-1324 PMID: 28402544
- 3. Nguyen G. 2006. Renin/prorenin receptors.. Kidney Int 69(9):1503-6 PMID: 16672920
- 4. Makowski N et al.. 2019. Enabling insights into the maturation of the renin-angiotensin-aldosterone system in children-Development of a low-volume LC-MS assay for the simultaneous determination of aldosterone, its precursor, and main metabolite.. Steroids 148:73-81 PMID: 31075338
- 5. McMahon C et al.. 2020. Synthetic nanobodies as angiotensin receptor blockers.. Proc Natl Acad Sci U S A 117(33):20284-20291 PMID: 32753386
- 6. Tonetta SA et al.. 1989. Intragonadal regulation of follicular maturation.. Endocr Rev 10(2):205-29 PMID: 2473895
- 7. Suessenbach FK et al.. 2019. Levels of angiotensin peptides in healthy and cardiovascular/renal-diseased paediatric population-an investigative review.. Heart Fail Rev 24(5):709-723 PMID: 31104255
- 8. Reis FM et al.. 2020. Angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas receptor in gonadal and reproductive functions.. Clin Sci (Lond) 134(22):2929-2941 PMID: 33196086
